©Viva Biotech (Shanghai) Ltd. 沪ICP备12042930号   Powerd by 

Exhibition at the 13th CHI Drug Discovery Chemistry Conference

2018/04/10 21:37
Viva has joined more than 750 high-level professionals to attend and exhibit at the annual CHI Drug Discovery Chemistry conference from April 2-6, 2018 in sunny San Diego, California.

Viva has joined more than 750 high-level professionals from all over the world to attend and exhibit at the annual CHI Drug Discovery Chemistry conference from April 2-6, 2018 in sunny San Diego, California. This is a highly anticipated event that brings scientists working in pharma, biotech and academia to discuss the cutting-edge technologies and the newest frontiers in small molecule drug discovery. It also attracts many experts in the interdisciplinary fields such as structural biology and biophysics. As one of the conference sponsors, the Executive Director of Biology Dr. James Zhao and the Executive Director of Business Development Yinghong Gao from Viva attended the conference.




Topics for many concurrent meeting tracks such as Protein-Protein Interactions, GPCR-Targeted Drug Design, Fragment-Based Drug Discovery, Small Molecules for Cancer Immunotherapy, Targeting Complex Membrane Proteins and Biophysical Approaches for Drug Discovery fit perfectly with the core expertise of Viva Biotech. It was extremely rewarding to hear from the attendees how Viva’s technology platforms and services had contributed to some of the works presented at the conference. Viva’s ASMS screening platform had also been listed in Dr. Pedro Serrano’s presentation on Takeda’s Tool Kit of Biophysics Methods. He further described how the innovative screening technologies had enabled them to tackle the challenges of working on many difficult drug targets. Two keynote presentations, one on Activity-Based Proteomics by Dr. Benjamin Cravatt and another on Targeting Ras and Myc by Dr. Stephen Fesik had drawn big crowds of attendees.




Viva’s exhibition booth had attracted many attendees who were passionate about drug discovery.  Some walked away being convinced that they could benefit from applying the innovative screening technologies showcased by Viva such as ASMS and SPR to their drug discovery programs, others had expressed strong interests in knowing more about our services in the areas such as structural biology, GPCR drug discovery and medicinal chemistry.




Yinghong also participated in two round table discussions, one on Fragment-Based Drug Discovery, another on Small Molecules for Cancer Immunotherapy. It was a wonderful experience to be able to sit down with a group of experts to pick each other’s brains and to share ideas and insights.


The networking opportunity to interact with renown professors from universities and industry leaders from big pharmas such as AstraZeneca, Pfizer, Abbvie, Genentech, GSK, Janssen and from smaller biotech companies such as Arbutus, FLX Bio is invaluable. It was a great time shared by all. 


After the event, we also have a better understanding of our clients’ potential needs and how Viva’s technology platforms and service areas may have the biggest impacts on the success of future drug discovery. It also allows us to keep abreast of the latest trends and to look beyond the horizon for future directions..